KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation.
Tanios S. Bekaii-Saab, Alexander I. Spira, Rona Yaeger, Gary L Buchschacher, Autumn Jackson McRee, Joshua K. Sabari, Melissa Lynne Johnson, Minal A. Barve, Navid Hafez, Karen Velastegui, James G Christensen, Thian Kheoh, Hirak Der-Torossian, Igor I. Rybkin Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ; US Oncology Research/Virginia Cancer Specialists, Fairfax, VA; Memorial Sloan Kettering Cancer Center, New York, NY; Southern California Permenente Medical Group, Los Angeles, CA; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Sarah Cannon Research Institute, Nashville, TN; Texas Oncology, Dallas, TX; Yale University School of Medicine, New Haven, CT; Mirati Therapeutics, Inc., San Diego, CA; Janssen Research and Development, LLC, San Diego, CA; Henry Ford Cancer Institute, Henry Ford Health System, Detroit, MI
Learn More here: https://ascopubs.org/doi/10.1200/JCO.2022.40.4_suppl.519?utm_medium=cpc&utm_campaign=J_Clin_Oncol_TrendMD_0&utm_source=TrendMD#.Yei3b8vXpqs.twitter
